Efletirizine

Drug Profile

Efletirizine

Alternative Names: UCB 28754

Latest Information Update: 02 Jun 2010

Price : $50

At a glance

  • Originator UCB
  • Class Acetates; Antiallergics; Antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Seasonal allergic rhinitis; Urticaria

Most Recent Events

  • 07 Jun 2005 Discontinued - Phase-II for Seasonal allergic rhinitis in USA (Intranasal)
  • 11 Feb 2005 UCB has completed a proof of concept trial of the once-daily formulation of efletirizine
  • 06 Jan 2004 UCB has completed phase III trials of twice-daily efletirizine in seasonal allergic rhinitis and urticaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top